STOCK TITAN

Addex Therapeutics corrects Hill grant to 1.32M options

Available on EDGAR Accepted by SEC EDGAR Learn about SEC filing dates
(Neutral)

Sentiment and the balance of points

Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.

Form Type
4/A

Rhea-AI Filing Summary

Addex Therapeutics Ltd. director Raymond George Hill received a corrected grant of 1,319,996 stock options on November 11, 2026, replacing the 942,854 options reported originally. The options vest in equal monthly installments over four years beginning on the exercisable date, carry a U.S.-dollar exercise price of $0.0260 per share, and expire November 10, 2036. The reported post-transaction option position was 1,593,103 shares.

Insider Hill Raymond George
Role Director
Type Security Shares Price Value
Grant/Award Stock-option (Right to Buy) F1, F3, F2 1,319,996 $0.00 $0.00
Holdings After Transaction: Stock-option (Right to Buy) — 1,593,103 options (Direct)
Holdings Before and After: Stock-option (Right to Buy), 273,107 to 1,593,103 options (Direct)
Footnotes (3)
  1. F1. This form 4/A is being filed to correct the number of stock-options reported as granted in the original Form 4 filed on November 13, 2026. The original filing incorrectly reported 942,854 stock-options granted. The correct number of stock-options granted on November 11, 2026 is 1,319,996.
  2. F2. The stock-options vest on equal monthly installments over a 4-year period beginning at the exercisable date. Each stock-option grants to right to purchase one ADXN share listed on SIX Swiss Exchange.
  3. F3. The exercise price is reported in U.S. dollars and reflects the conversion from CHF to USD at an exchange rate of $ 1.1995 per CHF 1.00 as of November 11, 2026.
Options granted 1,319,996 stock options Granted November 11, 2026; the amendment corrects the originally reported 942,854 options.
Exercise price $0.0260 per share Reported in U.S. dollars, converted from CHF at $1.1995 per CHF 1.00 as of November 11, 2026.
Post-transaction option position 1,593,103 shares Reported after the November 11, 2026 grant.
Previously reported grant 942,854 stock options Incorrect amount in the original report, corrected by the amendment.
stock-options financial
"correct number of stock-options granted on November 11, 2026"
equal monthly installments technical
"vest on equal monthly installments over a 4-year period"
exercise price financial
"The exercise price is reported in U.S. dollars"
The exercise price is the fixed amount at which you can buy or sell an asset, like a stock, when using an options contract. It matters because it helps determine whether exercising the option will be profitable or not, depending on the current market price. Think of it as the set price you agree on today to buy or sell later.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

How many stock options did Addex director Raymond George Hill receive?

Raymond George Hill received 1,319,996 stock options on November 11, 2026. The amendment corrects the original report, which stated 942,854 options.

What can Raymond George Hill purchase with each Addex option?

Each option grants the right to purchase one ADXN share listed on the SIX Swiss Exchange.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google
Add on Google
SEC Form 4
FORM 4UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number:3235-0287
Estimated average burden
hours per response:0.5
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
1. Name and Address of Reporting Person*
Hill Raymond George

(Last)(First)(Middle)
CHEMIN DES MINES 9

(Street)
GENEVACH-1202

(City)(State)(Zip)

SWITZERLAND

(Country)
2. Issuer Name and Ticker or Trading Symbol
Addex Therapeutics Ltd. [ ADXN ]
5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
XDirector10% Owner
Officer (give title below)Other (specify below)
2a. Foreign Trading Symbol
[ADXN]
3. Date of Earliest Transaction (Month/Day/Year)
11/11/2026
6. Individual or Joint/Group Filing (Check Applicable Line)
XForm filed by One Reporting Person
Form filed by More than One Reporting Person
4. If Amendment, Date of Original Filed (Month/Day/Year)
11/13/2026
Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year)2A. Deemed Execution Date, if any (Month/Day/Year)3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeVAmount(A) or (D)Price
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year)3A. Deemed Execution Date, if any (Month/Day/Year)4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year)7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeV(A)(D)Date ExercisableExpiration DateTitleAmount or Number of Shares
Stock-option (Right to Buy)(1)$0.026(3)11/11/2026A(2)1,319,99611/11/202611/10/2036Common Stock1,319,996$01,593,103D
Explanation of Responses:
1. This form 4/A is being filed to correct the number of stock-options reported as granted in the original Form 4 filed on November 13, 2026. The original filing incorrectly reported 942,854 stock-options granted. The correct number of stock-options granted on November 11, 2026 is 1,319,996.
2. The stock-options vest on equal monthly installments over a 4-year period beginning at the exercisable date. Each stock-option grants to right to purchase one ADXN share listed on SIX Swiss Exchange.
3. The exercise price is reported in U.S. dollars and reflects the conversion from CHF to USD at an exchange rate of $ 1.1995 per CHF 1.00 as of November 11, 2026.
/s/ Lenaic Nathanael Teyssedou by power of attorney11/16/2026
** Signature of Reporting PersonDate
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

Keep reading